Last Updated: September 2026
When should a sponsor implement an eTMF system? As early as your first study, and no later than the point where a trial moves beyond Phase 1, spans more than one country, or may face an inspection. An eTMF keeps your Trial Master File organized, traceable, and under your control, and the longer you wait to bring it in-house, the higher the migration risk and cost.
Below, we cover the triggers that signal it's time, how an in-house eTMF compares with a CRO-hosted one, and how several current eTMF options compare at a glance.
In this guide:
- Do Small Sponsors Need an eTMF System?
- What Challenges Arise Without an eTMF?
- How Does an eTMF Improve Inspection Outcomes?
- So When Should I Implement an eTMF System?
- In-House vs. CRO-Hosted eTMF
- How to Choose an eTMF System
- Comparing eTMF Vendors at a Glance
- How Kivo Supports eTMF Implementation
- Frequently Asked Questions
- Conclusion
When conducting clinical operations, particularly as studies progress from Phase 1 to Phase 2, the question may arise: When is the right time to integrate our own Electronic Trial Master File (eTMF) system? This article addresses the critical aspects of when and why organizations should consider implementing an eTMF, particularly focusing on the phases of clinical trials where its benefits are most pronounced.
Running and managing a clinical trial can be a daunting task, which is why so many organizations look for support and to outsource some activities. As sponsors increasingly outsource to CROs, so has using the CROs' eTMF system, rather than using an in-house solution. However, there are many benefits to bringing your TMF in house, such as improved visibility, increased control of your trial data, and mitigating the risk of data loss after the end of study transfer.
Whether you are partnering with a CRO or not, clinical study documentation and the requirements for managing content are very complex. This complexity exists during the active trial and for years (or decades) afterwards. Thus, you will need to have access to your data in an organized and secure eTMF system at SOME point. The longer you wait to migrate data into your own system, the higher the migration risk.
Do small sponsors need an eTMF System?
Absolutely. Gone are the days when having a proper eTMF system was a luxury for big pharma. As virtual inspections increase and the need for smooth End of Study transfers from Contract Research Organizations (CROs) to Sponsors gains momentum, eTMFs have transformed from being "nice to have" to becoming an indispensable tool for efficiently managing clinical study documents and inspections. After all, your data is your evidence of scientific merit. How this trial information is presented directly affects the outcome for regulatory approval.
Regulators have raised the bar on this. The ICH E6(R3) Good Clinical Practice guideline, finalized in January 2025 and adopted by FDA in September 2025, keeps ultimate responsibility for trial conduct with the sponsor even when work is delegated to a CRO, and expects essential records to be readily available for regulatory inspection. FDA's final guidance on conducting remote regulatory assessments, published in June 2025, also describes how the agency may request and review records remotely, which puts a premium on a TMF that is current and accessible on short notice.
What challenges arise without an eTMF?
Many organizations struggle with the complex requirements of managing and storing clinical trial data.
Why?
Here are some of the most common challenges we encounter:
- An incomplete understanding of the requirements around control and storage of documents, data, and correspondence
- A lack of investment into the people, processes, or tools needed to effectively manage the information
- A lack of visibility into how a third party / CRO is managing the data
Effectively managing the extensive data generated throughout the trial lifecycle necessitates robust systems and processes. Incorporating systems that streamline data collection, evaluation, and accessibility presents both a challenge and an opportunity. However, selecting the right systems and their timely implementation is pivotal, considering the intricate regulatory landscape and resource allocation constraints. Thus each organization needs to determine what factors affect their ability to bring its drug to market successfully, and align their regulatory processes, people, and tools accordingly.
How does an eTMF improve inspection outcomes?
Let’s think about what the main purpose of an eTMF really is. It is not just to store documents or data. It's actually the narrative structure of your trial that you will present to inspectors for regulatory approval.
When inspection day arrives, you want to present a clear story to your inspector. If your data is a mess - hard to access, multiple versions floating around, documents in different systems - it becomes much harder to paint a clear picture of your trial. Not to mention, if documents are mishandled along the way and the audit trail becomes broken, you risk having a poor inspection and possible delay to market.
A fit-for-purpose eTMF system not only mitigates the compliance issues, but can provide features like configurable access for inspectors, so you only present the information you want them to see, not draft documents. For a closer look at what sponsor-level oversight requires, see What an eTMF System Needs for Real Sponsor Oversight.
So when should I implement an eTMF system?
Organizations struggle with determining the best time to take control of their documentation and implement a system. Each phase in the lifecycle of a trial brings a different set of needs and challenges. The progression of the trial increases the volume of the data, requiring more control around the documentation. That said, an eTMF system can be implemented at any stage.
Here are few questions to ask yourself to determine if it's time to consider your own eTMF software:
- Do you have any studies?
- Is your program moving into the IND phase?
- Has your study progressed beyond Phase 1 – Safety?
- Will any of the studies be part of an inspection?
- Do any of your studies have more than one country involved?
- Are there components of your trial in Europe or the UK?
- What does your budget look like? Financial implications should not just be considered during the study, but the cost to transfer your study also should be considered.
Overall, the sooner you invest in an eTMF to support your studies the more compliant you will be, and it will help streamline the entire process. If you choose to wait and think lacking an eTMF will not affect the overall inspection, you may experience an unwelcome surprise.
In-house eTMF vs. CRO-hosted eTMF: what's the difference?
Many sponsors start with the CRO's system because it's already there. The trade-offs show up later, at oversight reviews, inspections, and study closeout. The table below summarizes how the two approaches typically differ; specifics depend on your CRO contract and your vendor.
| Consideration | CRO-hosted eTMF | Sponsor-owned eTMF |
|---|---|---|
| Oversight and visibility | Depends on the access and reporting the CRO provides | Direct, real-time view of filing status and completeness |
| Inspector access | Arranged through the CRO | Sponsor controls who sees what, including final-version-only access |
| End-of-study transfer | Records must be transferred out of the CRO's system at closeout, with migration risk | Records already live in your system; migration is needed only for studies already in flight |
| Consistency across studies | Each CRO may use its own system and structure | One structure and process across studies and CROs |
| Cost structure | Often bundled into CRO fees; ask about per-study and storage charges | Platform subscription plus internal time; ask each vendor about per-study, per-site, and storage fees |
| Internal effort | Lower day to day, less control | Requires a named owner for TMF quality and process |
Running an eTMF in-house doesn't mean building a department. Most teams need a named TMF owner, a filing plan aligned to the TMF Reference Model, a routine quality check for completeness and timeliness, and trained users across sponsor, CRO, and sites. For a line-by-line view of what that takes, see The True Cost of Building and Maintaining an In-House eTMF.
How to choose an eTMF System
Given its importance, the choice of what eTMF software to use is a big decision! We have written a short guide to help you evaluate eTMF providers, but in summary:
- Make sure it includes essential features such as document management, follows relevant compliance requirements such as CFR Part 11, and leverages best practices in security such as single-sign on or SOC 2 certifications.
- Evaluate the vendor themselves. Your eTMF vendor should feel like a partner - someone you can rely on for guidance and support when you need it.
- Understand the all-in cost of the system, including implementation fees, migration fees, per study fees, etc. Make sure you have a clear understanding of how the cost will grow if you scale.
Comparing eTMF Vendors at a Glance
This comparison is meant as a neutral starting point for your own evaluation, not an independent ranking. It doesn't assess implementation quality, market share, or fitness for your organization's specific needs. Validate any of the below directly with each vendor before deciding.
| Vendor | Platform Scope | Typical Fit | Compliance & Validation Approach |
|---|---|---|---|
| Kivo | Unified DMS, eTMF, RIM, and QMS on one shared document core | Clinical-stage sponsors and the CROs and consultancies supporting them, pre-IND through approval | Continuous CSA-aligned validation shipped with every release; native Part 11 e-signature included at no extra charge |
| Veeva Vault eTMF | eTMF application within the broader Veeva Vault clinical suite | Sponsors and CROs already standardized on Veeva's clinical applications, including larger programs | Vendor-managed, validated cloud environment |
| Montrium eTMF Connect | Dedicated eTMF platform organized around the TMF Reference Model | Pharma and biotech teams evaluating a standalone eTMF outside a larger operational suite | Positioned by Montrium around inspection readiness and sponsor oversight |
| Florence eTMF | eTMF connected to Florence's site-facing eBinders platform | Sponsors and CROs prioritizing document exchange directly with investigator sites | Part 11-oriented electronic records and signatures with role-based access |
How Kivo Supports eTMF Implementation
Kivo's eTMF runs on the same Part 11-compliant document core as its RIM and QMS modules, so clinical, regulatory, and quality teams work from one system instead of stitching tools together. For sponsors deciding when and how to bring a TMF in-house, the parts that matter most are:
- TMF migration. A validated process ingests documents, metadata, and audit trails from virtually any TMF platform or CRO and recompiles a single unified audit trail. Elevar Therapeutics moved 19 TMF studies, 73,794 documents in all, in 72 days.
- Inspection readiness. Inspector-specific licenses can be granted in minutes and show only final, non-draft document versions, aligned to the TMF Reference Model for easy navigation.
- Long-term storage. Kivo doesn't charge per GB or per study, and includes read-only document states, maintained audit trails, and quarterly data-integrity checks. See TMF Archiving After Study Closeout.
- Validation and security. Every release ships with CSA-aligned validation documentation, and Kivo is SOC 2 Type 2 and ISO 9001 certified.
Kivo is rated 4.9/5 on G2 and is used by 200+ sponsor, consultant, and CRO teams. Learn more about Kivo eTMF.
Frequently Asked Questions
When should a company implement an eTMF system?
Ideally with your first study, and no later than when a program moves beyond Phase 1, enters the IND phase, adds countries, or expects an inspection. An eTMF can be implemented at any stage, but the longer you wait, the more documents you must migrate and the greater the risk to audit-trail continuity.
Do small sponsors need their own eTMF if the CRO already has one?
In most cases, yes. A CRO's system may hold your TMF during the study, but under ICH E6(R3) the sponsor keeps ultimate responsibility for trial conduct. Your own eTMF gives you direct visibility, inspector-ready access, and a clean record when you change CROs or the study ends.
What are the pros and cons of an in-house vs. CRO-hosted eTMF?
A sponsor-owned eTMF gives you real-time oversight, control of inspector access, and no end-of-study transfer, but it needs someone to own TMF quality and process. A CRO-hosted eTMF reduces internal effort but limits visibility and can create transfer risk and extra cost at closeout.
What resources are needed to run an eTMF in-house?
You need a named TMF owner, a filing plan aligned to the TMF Reference Model, a routine quality check for completeness and timeliness, trained users at the sponsor, CRO, and sites, and a validated system with audit trails. Many teams pair the platform with vendor training and support rather than building capability alone.
What does it cost to implement and maintain an in-house eTMF?
Costs vary by vendor and pricing model. Ask about platform, validation, implementation, migration, per-study, per-site, and storage fees, and how they change as you add studies. Also count internal time for TMF quality control. Our cost breakdown for an in-house eTMF walks through these line items.
Conclusion
Having an eTMF to manage trial documents should not be delayed or put off until the end of a study. Even if you are using a CRO's system as your primary eTMF, you are regularly generating documents that should be in a controlled system at all times. If you have not considered implementing an eTMF for your clinical trial documents, now is a good time to begin the process of evaluating and implementing a system.
